NCT02485327View on ClinicalTrials.gov

PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Technosphere Insulin SAR439065 Afrezza®

"Pharmaceutical form: dry powder~Route of administration: oral inhalation"

Trial Locations (1)

55116

Investigational Site Number 276001, Mainz

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY